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The common g-chain (gc) plays a central role in
signaling by IL-2 and other gc-dependent cytokines.
Herewe report that activated T cells produce an alter-
natively spliced form of gc mRNA that results in pro-
tein expression and secretion of the gc extracellular
domain. The soluble form of gc (sgc) is present in
serum and directly binds to IL-2Rb and IL-7Ra pro-
teins on T cells to inhibit cytokine signaling and pro-
mote inflammation. sgc suppressed IL-7 signaling
to impair naive T cell survival during homeostasis
and exacerbated Th17-cell-mediated inflammation
by inhibiting IL-2 signaling upon T cell activation.
Reciprocally, the severity of Th17-cell-mediated
inflammatory diseases was markedly diminished
in mice lacking sgc. Thus, sgc expression is a natu-
rally occurring immunomodulator that regulates gc
cytokine signaling and controls T cell activation and
differentiation.
INTRODUCTION
Cytokines of the commong-chain (gc) family are critical for devel-
opment of T lineage cells and depend on gc for cellular signaling
(Rochman et al., 2009). gc deficiency results in a paucity of both
mature B and T cells because of impaired signaling by the gc
cytokine IL-7 (Noguchi et al., 1993). In fact, IL-7 signaling is
necessary for developing lymphocytes to proceed through the
pre-pro-B cell stage of B cell differentiation and the CD4CD8
double-negative (DN) stage of thymopoiesis (DiSanto et al.,
1995; Peschon et al., 1994; von Freeden-Jeffry et al., 1997).
Impaired IL-7 signaling also profoundly impairsmature T cell sur-
vival and homeostasis (Schluns et al., 2000; Tan et al., 2001).
Because gc is also required for IL-2 and IL-15 signaling, gc defi-
ciency impairs development of FoxP3+ regulatory T cells and NK910 Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc.cells (Heaney and Golde, 1996; Ma et al., 2006; Vosshenrich
et al., 2005) and also alters CD4 T helper cell lineage fate and
CD8 memory cell differentiation (Rochman et al., 2009). Thus,
gc governs the generation, differentiation, and homeostasis of
all lymphocyte subsets in the adaptive immune system.
Although gc expression is necessary for gc cytokine signaling,
gc alone cannot bind cytokines and cannot trigger downstream
signaling (Minami et al., 1993). Rather, gc cytokines induce gc
membrane proteins to complex with proprietary cytokine recep-
tor subunits, such as the IL-7-specific IL-7 receptor a chain
(IL-7Ra) and the IL-2-specific IL-2 receptor b-chain (IL-2Rb), to
transduce cytokine receptor signals. Importantly, the magnitude
and kinetics of gc cytokine responses are thought to be
controlled by the proprietary cytokine-specific receptor subunits
and not by gc (Rochman et al., 2009). For example, IL-7 stimula-
tion affects IL-7Ra expression but does not affect gc expression
(Park et al., 2004), and IL-2 stimulation affects IL-2Ra and IL-2Rb
without affecting gc expression (Depper et al., 1985; Siegel et al.,
1987). Consequently, modulation of gc expression is thought
to be irrelevant to either the kinetics or magnitude of cytokine
signaling. Instead, gc expression levels are thought to be devel-
opmentally set and to remain constant during T cell activation
and differentiation (Rochman et al., 2009).
In contrast to this prevailing view, we now report that modula-
tion of gc expression actively contributes to the regulation of
cytokine responses. Interestingly, gc exerts its regulatory effects
not as a conventional membrane receptor protein but as a
secreted protein induced by T cell stimulation. Specifically, we
found that activated T cells expressed a gcmRNA splice isoform
that resulted in production and secretion of soluble gc ectodo-
main proteins. Soluble gc inhibited cell signaling by gc cytokines
and exacerbated inflammatory responses by promoting differ-
entiation of pathogenic CD4+ Th17 cells both in vitro and in vivo.
Conversely, the severity of Th17-cell-mediated inflammatory
autoimmune disease was markedly diminished in mice lacking
sgc. Thus, this study identifies a role for gc as an active immuno-
regulatory molecule whose alternatively spliced form is secreted
to dampen signaling by gc cytokines and promote inflammatory
T cell immune responses in vivo.
Figure 1. Soluble gc Proteins Are Products
of Alternative Splicing
(A) Activated T cells express soluble gc proteins.
T cells were stimulated with a-TCR and a-CD28 in
the presence or absence of the metalloprotease
inhibitor TAPI2. Culture supernatants were har-
vested at indicated days and assessed for IL-2,
TNF-a, and soluble gc. Results are the summary of
three independent experiments.
(B) Immunoblot detection of sgc proteins in WT
and Il2rg/ sera. Serum samples were immuno-
precipitated (IP) with gc-ED-specific antibodies
and probed with the same antibodies in immuno-
blots (IB). Data are representative of five inde-
pendent experiments.
(C) Immunoblot detection of the sgc C-terminal 9
aa epitope. a-gc-ED immunprecipitated samples
were probed with custom-generated sgc C-ter-
minal 9 aa-specific antibodies. Data are repre-
sentative of five independent experiments.
(D) Generation of T cells that exclusively produce
membrane gc proteins. LN T cells from Il2rg/
andmgcTg were assessed for gc surface (left) and
mRNA expression (right). Cell surface gc expres-
sion (open histogram) versus control antibody
staining (shaded histogram) is shown for Il2rg/
and mgcTg LN T cells. Relative sgc and mgc
mRNA expression were determined by qRT-PCR
and normalized to expression in WT LN T cells,
which was set to 100%. Data are summary of
three independent experiments; ND indicates not
detectable.
(E) Serum sgc levels in WT, gcTg, Il2rg/, and
mgcTg mice. Data are the summary of three
independent experiments.
Error bars represent mean and SEM.
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Soluble gc Receptor Controls Cytokine SignalingRESULTS
Identification of a gc mRNA Splice Isoform that
Produces a Secreted Form of gc
T cell activation induces expression of soluble factors such as
IL-2 that control immune responses both in trans and in cis
(Malek, 2008). To further understand the role of such soluble fac-
tors, we analyzed culture supernatants of TCR- and CD28-stim-
ulated T cells. We found that culture supernatants from activated
T cells not only contained IL-2 and TNF-a, but surprisingly also
contained large amounts of a secreted form of membrane gc
proteins (Figure 1A). Although shedding is a classical mechanism
of producing soluble forms of membrane proteins (Heaney and
Golde, 1996), this was not the explanation for gc protein secre-
tion, as shown by the fact that inhibition of membrane metallo-
proteases by TAPI2 treatment to prevent membrane protein
shedding failed to prevent expression of soluble gc (Figure 1A).
Instead, we found that activated T cells upregulated expression
of a novel gc mRNA species that encoded a soluble form of gc
(sgc; soluble gc) rather than the conventional membrane form
of gc (Figures S1A–S1C available online).
The gene encoding gc (Il2rg) is composed of eight exons, and
the entire transmembrane (TM) domain is encoded in exon 6
(Cao et al., 1993). The new gc isoform was generated by alterna-
tive RNA splicing that excluded exon 6 to encode a gc protein
product with the full-length gc extracellular domain (ED) butwithout the TM and intracellular domain (ID) (Figures S1A and
S1B). Mechanistically, an open reading frame shift at the splice
junction of exon 5 to exon 7 created a new 9 amino acid epitope
followed by a stop codon. Notably, sgc transcripts were present
at low levels in resting T and B cells and were highly expressed in
immature thymocytes and NK cells as well as in activated T cells
(Figure S1D). Interestingly, we also identified alternatively spliced
sgc transcripts in human T cells, indicating an evolutionarily
conserved mechanism of soluble gc expression and regulation
(Figure S1E).
To examine whether sgc is expressed in vivo, we tested
serum for sgc proteins. C57BL/6 wild-type (WT) and gc-deficient
(Il2rg/) sera were immunoprecipitated with total gc-specific
antibodies and then probed with gc extracellular domain-spe-
cific antibodies (a-gc-ED). As shown in Figure 1B, sgc proteins
were detected in WT but not in Il2rg/ serum. To determine
whether serum sgc is a product of alternative splicing, we gener-
ated antibodies specific for the 9 residue C-terminal neoepitope,
CLQFPPSRI (Figure 1C), and used these antibodies to probe
anti-gc serum immunoprecipitates. Of note, the 9 residue neoe-
pitope is not present in the mouse proteome (NCBI Blastp anal-
ysis, data not shown), and it is unique to the alternatively spliced
sgc product. Immunoblot analysis showed immunoreactivity of
CLQFPPSRI-specific antibodies with WT but not Il2rg/ serum
(Figure 1C). To further examine whether shedding contributes to
sgc expression in vivo, we generated mice that were unable toImmunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc. 911
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Soluble gc Receptor Controls Cytokine Signalingproduce alternatively spliced sgc. We achieved this by gener-
ating a human CD2 mini-cassette-driven membrane gc trans-
gene (gcTg) and then breeding the transgene into Il2rg/ mice
to generate Il2rg/gcTg mice (referred to as mgcTg mice). In
mgcTg mice, all gc proteins are expressed from a prespliced,
transgenic gc cDNA that encodes only the full-length membrane
gc and cannot undergo splicing to produce the splice isoform.
mgcTg T cells expressed large amounts of membrane gc
mRNA and full-length gc protein, but no alternatively spliced
sgc transcripts (Figures 1D). Strikingly, serum from such mgcTg
mice lacked circulating sgc proteins, revealing that virtually all
serum sgc is generated by alternative splicing, with little or no
contribution from shedding (Figure 1E). Thus, mgcTg mice are
sgc deficient, and serum sgc is the product of a posttranscrip-
tional gc splice isoform.
Serum sgc Expression Is Upregulated upon Immune
Activation In Vivo
Having identified sgc produced by activated T cells in vitro, we
wished to know whether T cell activation would increase sgc
expression in vivo. To this end, we assessed serum sgc amounts
in BALB/c mice injected with CD3 antibodies (a-CD3) to induce
acute polyclonal T cell stimulation in vivo. In fact, serum sgc titers
were increased overnight after CD3 antibody injection concom-
itant with T cell activation even as total T cell numbers were not
increased (Figures 2A, S2A, and S2B).
Next, we wished to analyze serum sgc titer in mice with
chronically activated T cells. Ctla4/ mice contain chronically
activated T cells that mediate a lethal lymphoproliferative auto-
immune disease (Waterhouse et al., 1995). We found the amount
of serum sgc to be larger in Ctla4/ mice than in WT mice (Fig-
ure 2B). Importantly, elevated sgc titer was dependent on the
presence of activated T cells and not on Ctla4 deficiency itself,
because sgc expression was not elevated in nonautoimmune
Ctla4/Cd28/ mice that lack activated T cells and conse-
quently are disease free (Figure 2B; Tai et al., 2007). To further
assess sgc expression during in vivo immune activation, we
also analyzed autoimmune Il2/ and CD25-deficient (Il2ra/)
mice. Both mouse strains have defective CD4+ regulatory
T cell generation that results in massive in vivo T cell activation
and lethal autoimmunity (Sadlack et al., 1993; Willerford et al.,
1995). We found that both Il2/ and Il2ra/ mice expressed
increased amounts of serum sgc, confirming that sgc expression
was elevated during in vivo immune activation (Figure 2C).
Collectively, our results demonstrate that serum sgc protein
levels are increased during T cell activation in vivo.
Generation of sgc Transgenic Mice
To understand the effect of increased sgc expression, we gener-
ated transgenic mice overexpressing sgc in T cells (sgcTg).
In sgcTg mice, serum sgc levels were substantially increased
(Figures 2D and 2E), but T cell numbers and phenotypes were
unchanged fromWTmice (Figures 2F, S2C, and S2D). To assess
whether in vivo sgc upregulation had any effect on T cells, we
stimulated sgcTg CD4+ T cells with PMA/ionomycin and exam-
ined their ex vivo cytokine expression profiles. gc cytokines
play an instructive role in CD4 effector T cell differentiation
(Zhu et al., 2010), and we wished to know how in vivo exposure
to increased sgcwould affect T cell function. Interestingly, sgcTg912 Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc.CD4+ T cells contained higher proportions of IFN-g producers
than did WT CD4+ T cells (Figure 2G). Expression of the Th2
cytokine IL-4, however, was not affected (Figure S2E). Notably,
sgcTg CD4+ T cells contained a significantly larger population
of IL-17-producing cells (p < 0.001), suggesting that increased
sgc level promoted a Th1- and Th17-cell-prone proinflammatory
environment (Figure 2G), but this could also reflect an increased
presence of memory cells. Importantly, such settings were not
created by defects in FoxP3+ CD4+ Treg cells as shown by
the fact that both development and function of Treg cells were
unaffected in sgcTg mice (Figures S2F and S2G).
sgc Is Proinflammatory and Exacerbates EAE Pathology
Because IL-17-producing Th17 cells are potent inducers
of cell-mediated autoimmunity (Harrington et al., 2005; Park
et al., 2005), we wished to know whether sgc would promote
autoimmunity. Experimental autoimmune encephalomyelitis
(EAE) is a cell-mediated neuroimmunological disease that is
largely mediated by Th17 cells and serves as an experimental
model for human multiple sclerosis (Goverman, 2009). Injection
of MOG peptides results in the activation and brain infiltration
of autoreactive lymphocytes, which, in our hands, induced paral-
ysis that peaked around day 5 after onset of the disease. Strik-
ingly, when assessing serum sgc expression in EAE-induced
mice,we found increased sgc levels in diseasedmice (Figure 3A).
To understand whether increased sgc expression contributed to
or was the consequence of EAE pathology, we assessed disease
progression and found sgcTg mice to be significantly more sus-
ceptible to EAE than control mice (p < 0.001) (Figure 3B). In fact,
in every parameter examined, sgcTgmice displayed amore pro-
nounced phenotype than did WT mice. Specifically, we found
in sgcTg mice that EAE severity worsened, disease progression
accelerated, and disease recovery was substantially delayed
(Figure 3C). Moreover, we found increased numbers of spinal-
cord-infiltrating CD4+ T cells, which correlated with dramatically
increased percentages and numbers of Th1 and Th17 cells
and IL-17, IFN-g double-producing CD4+ T cells (Figures 3D
and 3E). Taken together, these results indicate that sgc en-
hances inflammatory immune responses and increases differen-
tiation of pathogenic Th17 CD4+ effector cells in vivo.
sgc Impairs IL-2 Signaling
Having observed that sgc expression exacerbated T-cell-medi-
ated autoimmune diseases in vivo, we wished to determine the
effect of soluble gc proteins on the generation of inflammatory
Th17 cells. Th17 cell differentiation is negatively regulated by
IL-2 signaling (Laurence et al., 2007) and is increased by inhibi-
tion of IL-2 signaling (Chen et al., 2011; Pandiyan et al., 2007).
Therefore, we wished to know whether increased Th17 cell gen-
eration in sgcTgmice was the result of diminished IL-2 signaling.
To this end, we produced sgc as recombinant proteins (rsgc)
(Figure S3). Importantly, we found that rsgc proteins were ex-
pressed as disulfide-linked homodimers (Figure 4A), and that
the same was true for endogenously produced sgc proteins
in serum (Figure S4A). In fact, alternative splicing of gc in both
humans and mice creates a C-terminal cysteine residue that
promotes dimerization of sgc proteins (Figures S1A and S1E).
Therefore, unlike membrane gc proteins, sgc proteins exist
as dimers.
Figure 2. sgc Expression Is Induced by T Cell Activation In Vivo
(A) Serum sgc levels in BALB/c mice injected overnight with a-CD3 antibodies. ELISA data are summary of two independent experiments with two mice per
group.
(B and C) Serum sgc levels in Ctla4/ and Ctla4/Cd28/, and in Il2/ and Il2ra/ mice. ELISA data are summary of three independent experiments.
(D) sgc protein expression in WT and sgcTg mice sera. Serum samples were immunoprecipitated with gc-ED-specific antibodies and probed with the same
antibodies in immunoblots. Numbers in box indicate densitometric quantification of sgc expression. Data are representative of five independent experiments.
(E) Relative sgc levels in WT and sgcTg serum. ELISA data are summary of five independent experiments.
(F) LN cell profiles of WT and sgcTg mice. Data are representative of 17 independent experiments.
(G) IFN-g and IL-17A expression in sgcTg CD4+ LN T cells. CD4+ LN T cells from WT and sgcTg mice were stimulated for 3 hr with PMA and ionomycin and
assessed for IFN-g and IL-17A expression by intracellular staining. IFN-g, IL-17A profile is representative of six independent experiments (left). Bar graph shows
percent IFN-g- or IL-17A-producing CD4+ T cells.
Error bars represent mean and SEM.
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Soluble gc Receptor Controls Cytokine SignalingBecause gc has no affinity for IL-2 (Minami et al., 1993), solu-
ble gc would not diminish IL-2 signaling by binding free IL-2.
Thus, we wished to know whether sgc might diminish IL-2
signaling by binding to IL-2 receptor proteins on the cell surface.
To test this idea, we performed surface plasmon resonance
(SPR) studies with purified rsgc on immobilized IL-2Rb extracel-
lular domain (ED) proteins. Strikingly, SPR analysis showed thatsgc proteins directly bound to IL-2Rb-ED and that dimeric sgc
proteins bound much more strongly (Kd of 16.6 ± 5.5 mM) than
monomeric sgc (Kd of 695 ± 76 mM) (Figure 4B). Of note, we
consider that the theoretical affinity of sgc binding measured
by in vitro SPR study reflects only the minimum potential affinity
of sgc for IL-2Rb and that sgc would bind to actual cell surface
IL-2Rb with much higher affinity under physiological conditions.Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc. 913
Figure 3. sgc Is Proinflammatory and Exacerbates EAE Disease Progression
(A) Serum sgc in EAE-induced mice. sgc was assessed by immunoprecipitation and immunoblot before (day 0) and after (day 15) EAE induction in WTmice. Blot
shows representative serum sgc expression of four independent experiments.
(B) EAE induction in WT and sgcTg mice. EAE clinical scores are representative of seven independent EAE experiments, each with five mice per group.
(C) EAE disease course in WT and sgcTg mice. Data are summary from seven independent experiments, each with five mice per group.
(D) Th1 and Th17 cell subset analysis of spinal-cord-infiltrating CD4+ T cells in EAE-induced WT and sgcTg mice. IL-17A, IFN-g profile is representative of two
independent experiments with two mice per group.
(E) Spinal-cord-infiltrating CD4+ T cell numbers in EAE-induced mice. On day 14 after immunization, IFN-g- and/or IL-17A-producing CD4+ T cells were
enumerated from spinal cords of WT and sgcTg mice. Data are representative for two independent experiments with two mice per group.
Error bars represent mean and SEM.
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Soluble gc Receptor Controls Cytokine SignalingTo further assess whether sgc directly binds to T cells, we uti-
lized flow cytometry. To do so, we examined TCRb+ mature
thymocytes of mice with conditional deletion of gc in DP thymo-
cytes (Il2rgfl/flE8IIICre) because they lack surface gc expression
(Figure S4B; McCaughtry et al., 2012). Notably, incubation of
Il2rgfl/flE8IIICre thymocytes with rsgc proteins revealed direct
binding of sgc to the surface, which we visualized by staining
with gc-specific antibodies (Figure 4C) and which was still914 Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc.detectable at 0.06 mg (10 nM) (Figure 4D). More importantly,
addition of IL-2 significantly increased (p < 0.0001) sgc binding
to Il2rgfl/flE8IIICre cells (Figures 4C and 4D), indicating that sgc
affinity to IL-2Rb is increased by IL-2. In sum, sgc proteins,
especially dimeric sgc proteins, directly bind to surface IL-2Rb
chains, especially in the presence of IL-2.
To directly test whether sgc binding to IL-2Rb suppressed
IL-2 signaling in T cells, we assessed IL-2-induced STAT5 and
Figure 4. sgc Inhibits IL-2 Signaling
(A) Dimer formation of recombinant sgc proteins. Recombinant sgc proteins were expressed in insect cells and were resolved in SDS-PAGE under reducing
(+DTT) and nonreducing conditions. sgc was detected with antibodies against the gc-ED. Immunoblot is representative of four independent experiments.
(B) sgc binding affinities to IL-2Rb determined by SPR. Binding sensorgrams of monomeric (left) and dimeric (right) sgc to immobilized IL-2Rb. The insets show
dose-response curves of the maximal responses (Rmax, depicted by the dashed boxes) for each sgc concentration. Plots of Rmax versus sgc concentrations were
nonlinear fit to a single-site binding affinity model to determine Kd values.
(C) Recombinant sgc binding to mature Il2rgfl/flE8IIICre thymocytes. Il2rg
fl/flE8IIICre thymocytes (1.53 10
6 cells in 100 ml) were incubated for 3 hr with 2 mg rsgc in
the presence or absence of IL-2 (200 ng) and assessed with gc antibodies for surface gc staining. Histograms show surface gc staining on TCRbhi thymocytes.
(D) Titration of sgc binding to Il2rgfl/flE8IIICre thymocytes. Il2rg
fl/flE8IIICre thymocytes were treated with increasing amounts of rsgc in the presence or absence of
IL-2 (200 ng) as described above. Data are the summary of three independent experiments (mean and SEM).
(E) Recombinant sgc impairs proximal IL-2 signaling. CD8+ T cells were stimulated with IL-2 in the presence (4 mg/ml rsgc) or absence (Veh; vehicle) of rsgc and
assessed for pSTAT5 (left) or pAKT contents (right). Line graphs show fold induction of IL-2-induced STAT5 or AKT phosphorylation over cells treated with Veh
alone. Data are the summary of four independent experiments (mean and SEM).
(F) Recombinant sgc inhibits IL-2-induced T cell proliferation. CFSE-labeled WT CD8+ LN T cells were stimulated with IL-2 in the presence or absence of rsgc.
CFSE dilution was analyzed at the indicated time points. Histograms are representative of five independent experiments.
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Soluble gc Receptor Controls Cytokine SignalingAKT phosphorylation in the presence or absence of rsgc (Malek,
2008). We found that rsgc effectively suppressed downstream
IL-2 signaling (Figure 4E) and that rsgc-induced impairment
of IL-2 signaling reduced IL-2’s biological effects on T cells. In
mice, naive CD8+ T cells respond to IL-2 by vigorous prolifera-
tion (Cho et al., 2010). We confirmed such IL-2-induced prolifer-ation in purified CD8+ T cells and found that rsgc suppressed
IL-2-driven proliferation in the same cells (Figure 4F), demon-
strating a direct inhibitory role of sgc in IL-2 signaling. Thus,
by binding to IL-2Rb proteins on the cell surface, sgc prevents
association with membrane gc proteins to impair IL-2 signaling
(Figure S4C).Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc. 915
Figure 5. sgc Promotes Th17 Cell Differentiation of CD4+ LN T Cells
(A) sgc promotes IL-17A expression. Sorted naive CD4+ T cells were stimulated under Th17-cell-polarizing conditions and assessed for intracellular IL-17A and
IFN-g expression. Where indicated, recombinant human IL-2 (rhIL-2), neutralizing mouse IL-2-specific antibodies (a-mIL-2), recombinant sgc (4 mg/ml rsgc), or
vehicle (Veh) were added at the beginning of the culture. Data are representative of ten independent experiments.
(B) Summary of IL-17A+CD4+ T cell differentiation under modified Th17-cell-polarizing conditions. Each symbol represents an individual experiment under the
indicated condition as described above.
(C) IL-17A secretion in WT and sgcTg CD4+ T cells. Culture supernatants were collected at day 4 of Th0 or Th17 cell differentiation cultures. ELISA data are
representative for five independent experiments.
(D) Redundant effect of rsgc and mIL-2-specific antibodies on Th17 cell differentiation. Naive CD4+ T cells were stimulated under Th17-cell-polarizing conditions
in the presence of rsgc or mIL-2-specific antibodies. Each symbol represents an individual mouse.
(E) sgc effect on IL-17A expression under IL-2-deficient conditions. Naive CD4+ T cells were stimulated under Th17-cell-polarizing conditions to assess
intracellular IL-17A and IFN-g expression. Where indicated, rsgc were added at the beginning of the differentiation culture. Contour plots are representative of
four independent experiments (left). Bar graph shows percent increase of IL-17A-producing CD4+ T cells by rsgc treatment compared to vehicle control.
Error bars represent mean and SEM.
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Soluble gc Receptor Controls Cytokine Signalingsgc Promotes Th17 Cell Differentiation by Suppressing
IL-2 Signaling
To assess the IL-2 inhibitory effect of sgc on Th17 cell differenti-
ation, we analyzed Th17 cell generation by using in vitro cultures
in the presence of rsgc. As previously described (Laurence et al.,
2007), recombinant IL-2 potently suppressed, whereas antago-
nizing IL-2 antibodies substantially enhanced, Th17 cell differen-
tiation (Figures 5A and 5B). Importantly, sgc treatment or sgc
overexpression had the same effect as IL-2 antibodies as it
increased both the proportion of IL-17-producing cells and over-916 Immunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc.all IL-17 expression (Figures 5B and 5C). In fact, coincubation
of rsgc and antagonizing IL-2 antibodies did not have additive
effects, indicating that the Th17-cell-promoting mechanisms of
rsgc and IL-2 antibodies were redundant (Figure 5D).
To further demonstrate that the sgc effect on Th17 cells was
due to its inhibition of IL-2 signaling, we analyzed sgc effects
on CD4+ T cells from Il2/ mice. We stimulated naive Il2/
CD4+ T cells under Th17 cell conditions with or without rsgc
and found that unlike the effect of sgc on WT T cells, sgc failed
to increase IL-17 expression in Il2/ T cells (Figure 5E). Identical
Immunity
Soluble gc Receptor Controls Cytokine Signalingresults were observed in Il2/sgcTg CD4+ T cells where sgc
transgene expression failed to enhance Th17 cell differentia-
tion compared to Il2/ cells (Figure 5E). Altogether, these re-
sults document that sgc promotes Th17 cell differentiation by
specifically impairing IL-2 signaling.sgc Deficiency Ameliorates Th17-Cell-Mediated
Inflammatory Autoimmune Diseases
Because sgc exacerbated IL-17 expression and inflammation,
we wished to know whether the absence of sgc would dampen
inflammatory responses that otherwise occurred in WT mice. To
this end, we assessed EAE induction inmgcTgmice that express
only transgenic membrane gc receptors and lack endogenous
sgc proteins (Figure 1E). Strikingly, EAE disease progression in
mgcTg mice was dramatically reduced compared to WT mice,
with delayed disease onset and lower clinical scores (Figure 6A).
Analysis of spinal-cord- and brain-infiltrating T cells further
revealed a significant reduction in inflammatory CD4+ T cell
numbers and greatly diminished percentages of IL-17-IFN-g
double producers, demonstrating a protective effect of sgc defi-
ciency in mgcTg mice (Figures 6B and 6C). Importantly, the
severity of inflammatory reactions was markedly reduced in
mgcTg mice despite the presence of normal numbers and
appearances of peripheral T cells (Figures S5A and S5B).
To further assess the ameliorative effect of sgc deficiency, we
utilized the CD4+CD45RBhi T cell transfer model of inflammatory
bowel disease (IBD) (Powrie et al., 1993). Adoptive transfer of
naive T cells into immunodeficient Rag2/ mice results in se-
vere autoimmune inflammatory colitis that can be monitored by
body weight loss and increased IBD clinical scores (Table S1).
Notably, we found that Rag2/ host mice injected with mgcTg
CD4+ T cells had markedly diminished IBD, whereas Rag2/
mice injected with WT CD4+ T cells suffered from significant
body weight loss, destruction of colon tissues, and rapid deteri-
oration of health (Figures 6D, 6E, S5C, and S5D). Importantly,
adoptively transferred mgcTg CD4+ T cells were still activated
in vivo and produced large amounts of IFN-g, but it was specif-
ically the expression of proinflammatory IL-17 that was dramat-
ically diminished in these cells (Figure 6F). Thus, sgc-deficient
T cells were unable to induce severe autoimmune IBD because
of reduced Th17 cell generation. Conversely, T cell expression
or overexpression of sgc increased the severity of inflammatory
disease (Figure S5D). These results reveal that sgc exacerbates
in vivo inflammatory immune responses and contributes to the
severity of in vivo autoimmune pathology.sgc Overexpression Impairs T Cell Development and
Naive T Cell Homeostasis
Although sgc directly binds to LN T cells (Figure 7A), resting
T cells do not express high levels of IL-2Rb. These data sug-
gested that sgc also bound to receptors for cytokines other
than IL-2. Specifically, we considered that sgc might bind to
IL-7 receptors because they are highly expressed on all resting
T cells. SPR analysis showed that this was indeed the case.
We found that sgc proteins directly interacted with mouse
IL-7Ra-ED proteins and that dimeric sgc showed a dramatic in-
crease of IL-7Ra-ED binding activity (Kd = 3.9 mM) over mono-
meric sgc proteins (Kd = 50.8 mM) (Figure 7B and Table S2).To further demonstrate sgc binding to surface IL-7Ra proteins,
we incubated Il2rgfl/flE8IIICre thymocytes with rsgc proteins and
assessed rsgc binding to thymocyte subpopulations. TCRbhi
mature thymocytes express high levels of IL-7Ra and strongly
bound sgc, whereas DP thymocytes do not express surface
IL-7Ra and did not bind sgc (Figure 7C). To directly show that
recombinant sgc specifically bound to IL-7Ra proteins, we
examined gc-deficient TCRbhi thymocytes that were additionally
deficient in IL-7Ra (McCaughtry et al., 2012). Indeed, IL-7Ra
deficiency substantially reduced sgc binding to sgc-deficient
TCRbhi thymocytes (Figure 7D), documenting that sgc directly
binds and interacts with surface IL-7Ra proteins.
IL-7 is critical for thymopoiesis and impaired IL-7 signaling
results in reduced thymus cellularity (von Freeden-Jeffry et al.,
1995). Notably, increased sgc expression in sgcTgmice resulted
in decreased total thymocyte numbers (Figure 7E). CD25 is
highly expressed on immature DN thymocytes but dilutes out
with proliferation so that CD25 is normally absent on DP thymo-
cytes. However, sgcTg DP thymocytes still expressed significant
amounts of surface CD25, which indicated impaired IL-7
signaling and impaired expansion of DN cells (Figure S6A;
Crompton et al., 1994). These results demonstrate that sgc
blocks in vivo IL-7 signaling. In further support of an sgc effect
on IL-7 signaling, we observed increased T cell apoptosis and
reduced percentages and numbers of naive T cells in sgcTg
mice (Figures 7F and 7G), even as their T cells expressed iden-
tical levels of IL-7Ra and other gc family receptors to WT mice
(Figure S6B). Moreover, adoptive transfer of WT T cells into con-
genic sgcTg or WT host mice revealed that survival of CD44lo
naive donor T cells was substantially reduced in sgcTg hosts
compared to WT hosts (Figure S6C). Finally, to directly demon-
strate that sgc blocks IL-7-induced survival, we stimulated naive
T cells with IL-7 in vitro and assessed the effect of recombinant
sgc on cell survival. As shown in Figure S6D, rsgc effectively
blocked IL-7-induced T cell survival in vitro. Thus, sgc inhibited
IL-7 signaling during both T cell development and peripheral
T cell homeostasis.
DISCUSSION
Herewe report a regulatory mechanism of gc signaling that tunes
T cell responsiveness to IL-2 and IL-7 and potentially to other gc
cytokines as well. This regulatory pathway was based on post-
transcriptional generation and secretion of the gc extracellular
domain that directly bound to gc cytokine proprietary receptors
such as IL-2Rb and IL-7Ra, especially in the presence of
cytokines, and interfered with cytokine signaling. Importantly,
secreted gc proteins required disulfide-linked homo-dimerization
forhigh-affinity bindingand inhibitionof cytokinesignaling.During
steady-state conditions, sgc interfered primarilywith IL-7-depen-
dent processes, resulting in impaired thymopoiesis and naive
T cell survival. During T cell activation, sgc inhibited IL-2 signaling
and promoted the development of proinflammatory Th17 cell
responsesas demonstratedby increasedTh17cell differentiation
in vitro and by exacerbation of EAE disease in sgc transgenic
mice in vivo. Conversely, in vivo sgc deficiency suppressed
Th17 cell differentiation and dramatically reduced the severity
of inflammatory autoimmune disease, resulting in markedly
improved disease outcomes. Thus, this study identifies sgcImmunity 40, 910–923, June 19, 2014 ª2014 Elsevier Inc. 917
Figure 6. sgc Deficiency Is Protective against Inflammatory Autoimmune Diseases
(A) EAE induction in WT and mgcTg mice. EAE clinical scores are summary of two independent EAE experiments, each with four mice per group.
(B) Th1 and Th17 cell subset analysis of spinal-cord- and brain-infiltrating CD4+ T cells in EAE-induced WT and mgcTg mice. Contour plots show representative
IL-17A, IFN-g profiles from four mice per group.
(C) Spinal-cord- and brain-infiltrating CD4+ T cell numbers in EAE-inducedmice. On day 15 after immunization, IFN-g- and/or IL-17A-producingCD4+ T cells were
enumerated from spinal cords and brains of WT and mgcTg mice. Data are representative of four mice per group.
(legend continued on next page)
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Soluble gc Receptor Controls Cytokine Signalingproteins as endogenous immunomodulators that exacerbate
in vivo inflammatory diseases by directly binding to cytokine re-
ceptors and dampening T cell responses to gc cytokines.
Cytokine signaling in T cells is tightly controlled at many levels.
Expression of cytosolic inhibitory molecules, such as SOCS,
limits the magnitude and duration of cytokine signaling (Yoshi-
mura et al., 2007). Upregulation of surface cytokine receptor
expression, on the other hand, positively affects cytokine
signaling. Secretion of gc proteins now adds another layer of
regulatory complexity because sgc expression is upregulated
upon T cell activation but, unlike the upregulation of other IL-2 re-
ceptor chains that enhance IL-2 signaling, upregulation of sgc
suppresses IL-2 signaling. Moreover, soluble gc is unique in its
regulatory mechanism because it suppressed IL-2 signaling
without binding to the IL-2 molecule itself. This is in contrast to
other chains of the IL-2 receptor complex that regulate IL-2
responsiveness by direct interaction with IL-2 (Minami et al.,
1993). Because IL-2 signaling requires membrane gc associa-
tion with IL-2Rb, sgc binding to IL-2Rb proteins probably blocks
IL-2 signaling by preventing recruitment of membrane gc pro-
teins and assembly of signaling-competent IL-2 receptor/mem-
brane gc complexes.
The secreted gc protein is structurally identical to the mem-
brane gc receptor, except for absent transmembrane and intra-
cellular domains. Because ligand binding is mediated by the
extracellular domain, it was initially unclear how soluble gc could
compete with membrane gc for binding to proprietary receptor
proteins. The mechanism was partly revealed by SPR analysis,
which showed that dimeric sgc proteins possessed >40-fold
increased affinity of binding to IL-2Rb proteins compared to
monomeric sgc proteins, which was further enhanced in the
presence of cytokines. Thus, serum sgc proteins, which are
mostly dimers, are vastly superior in binding to IL-2Rb than
membrane gc proteins, which are monomers and do not display
anymeaningful affinity to IL-2Rb (Rickert et al., 2004). As a result,
sgc proteins effectively outcompete membrane gc protein for
binding to proprietary cytokine receptors IL-2Rb and IL-7Ra.
Therefore, upon dimerization, sgc proteins acquire binding
specificities that make them distinct from monomeric sgc and
membrane gc proteins. In this regard, we think it is not a coinci-
dence that alternative splicing of sgc pre-mRNA creates a new
C-terminal cysteine residue that promotes disulfide linkage and
dimerization of sgc proteins. Indeed, we found such de novo
C-terminal cysteine residues in both mouse and human sgc pro-
teins, indicating that dimerization of sgc proteins is an evolu-
tionary conserved mechanism of regulating cytokine signaling.
Soluble cytokine receptors have been observed in previous
studies (Baran et al., 1988; Mortier et al., 2004; Nielsen et al.,
1998). Expression of soluble cytokine receptors had been asso-
ciated with inflammation, autoimmunity, and cancer (Heaney
and Golde, 1996), but it was uncertain whether their expression
was the cause or the consequence of immune activation. In
theory, soluble cytokine receptors might either potentiate or(D) Body weight change of IBD-inducedmice. Rag2/mice were injected with ea
body weights. Data show results from four mice per group.
(E) Colon histology from Rag2/ host mice injected with naive CD4+ T cells from
(F) Th1 and Th17 cell subset analysis in CD4+ LN T cells from IBD-induced WT an
Error bars represent mean and SEM.antagonize cytokine signaling (Heaney andGolde, 1996). Soluble
IL-6Ra, for example, directly binds IL-6 and potently enhances
IL-6 signaling (Rose-John, 2012), whereas soluble IL-15Ra se-
questers IL-15 and prevents it from binding to membrane IL-15
receptors (Mortier et al., 2004). gc proteins, however, do not
show significant binding affinity to free cytokines, so it was not
immediately obvious what role soluble gc would play in cytokine
signaling. By using recombinant sgc proteins and sgc transgenic
mice, we have demonstrated that sgc antagonizes IL-2 and IL-7
signaling and increases inflammatory immune responses.
Because T cell activation induces sgc production and sgc in
turn induces inflammatory cytokine expression, sgc production
is a mechanism to reinforce proinflammatory immune responses
downstream of T cell activation. In fact, sgc expression would
limit IL-2 responses and promote effector T cell differentiation.
Thus, our present results provide an explanation for earlier re-
ports on soluble gc expression in which a significant correlation
was found in Crohn’s disease patients between disease activity
and serum gc levels (Nielsen et al., 1998). According to our pre-
sent findings, increased soluble gc expression would dampen
gc cytokine signaling, which would enhance inflammatory cell
activation to worsen the disease outcome. In agreement with
our perspective, soluble gc is highly expressed under inflamma-
tory conditions in both humans and mice. Soluble gc was abun-
dantly expressed in synovial fluid of patients with rheumatoid
arthritis and also highly induced in mice challenged with
L. major (Meissner et al., 2001; Nishio et al., 2001). We also found
that EAE disease outcome and in vivo inflammatory responses
were exacerbated in sgcTg mice. Collectively, these data indi-
cate a role for sgc as an active inducer of pathogenic T cells
and inflammation.
Because sgc promotes inflammation, it is interesting to
speculate whether neutralization of serum sgc expression would
ameliorate inflammatory disease and dampen destructive T cell
responses. The striking reduction in disease severity of EAE or
IBD-induced mgcTg mice lacking sgc observed here suggests
that depletion of sgc might be an effective therapy in patients
suffering from inflammatory immune diseases. In this regard,
the 9 aa C-terminal neoepitope CLQFPPSRI (and the 7 aa neoe-
pitope RCPEFPP in humans) of sgc provides an excellent tar-
get for intervention with neutralizing antibodies. These peptide
epitopes are generated only upon alternative splicing of gc
pre-mRNA exon 5 to exon 7, and they are found only in sgc
and not in membrane gc proteins. In contrast to conventional
gc-specific antibodies, C-terminal sgc-specific antibodies will
neutralize only alternatively spliced sgc proteins, making this
epitope an attractive target to clear sgc from circulation without
affecting membrane gc receptor function.
Discovery of the unique C-terminal sgc epitope was enlight-
ening because it helped us identify the molecular origin of sgc.
Specifically, the 9 aa C-terminal sequence is not found in mem-
brane gc proteins so that its presence in serum directly demon-
strated that sgcproteins are products of alternativeRNAsplicing.ch 0.5millionWT or mgcTg CD4+CD45RBhi T cells andmonitored for change in
the indicated donor mice at 6 weeks after T cell transfer.
d mgcTg mice (left). Data show results from three mice for each group (right).
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Soluble gc Receptor Controls Cytokine SignalingSoluble cytokine receptors are usually produced by one of the
following twomajormechanisms; proteolytic cleavage and shed-
ding of membrane cytokine receptors or alternative splicing of
cytokine receptor pre-mRNA (Levine, 2004). TNF receptors are
classical examples of cytokine receptors that are cleaved by
transmembrane metalloproteinases and shed from cells (Hwang
et al., 1993). Soluble IL-6 receptors, on the other hand, are usually
generated by alternative splicing (Horiuchi et al., 1994). Our
data document that sgc is exclusively produced by alternative
splicing. It is conceivable that genetic variations might also
contribute to increased sgcexpression. In fact, IL-7Ragenepoly-
morphisms can result in increased expression of soluble IL-7Ra
(sIL7Ra) (Gregory et al., 2007), and sIL7Ra expression has been
proposed as a significant risk factor for multiple sclerosis in hu-
mans (Harley, 2007; Lundstro¨m et al., 2013). Specifically, these
SNPs led to exclusion of exon 6during IL-7Rapre-mRNAsplicing
and resulted in the deletion of the transmembrane domain to
produce soluble IL-7R proteins (Goodwin et al., 1990; Gregory
et al., 2007). It would be interesting to assessgc genes for genetic
variations that increase exon 6 exclusion and to test whether
such SNPs are associated with increased risk for MS or other
autoimmune disease. Potentially, such gc genetic variations
could predispose carriers to excessive inflammatory responses
by increased levels of sgc.
In conclusion, the present study has identified sgc as
an endogenous regulatory mechanism that dampens T cell
signaling to gc cytokines and results in enhanced activity of
Th17 cells. Enforced sgc expression constrained T cell survival
under homeostatic conditions and promoted a proinflammatory
environment under immune activation. Reciprocally, in vivo sgc
deficiency suppressed inflammatory Th17 cell differentiation
and effectively reduced the severity of Th17-cell-mediated auto-
immune disease. Thus, sgc represents a naturally occurring
immunomodulator of T cells and introduces a target for interven-
tion in inflammation and disease.EXPERIMENTAL PROCEDURES
Animals
C57BL/6 (B6) mice and B6.Ly5.2 mice were obtained from the Jackson Labo-
ratory. Ctla4/, Ctla4/Cd28/, Il2/, Il2ra/, Rag2/, and Il2rg/ mice
were bred in our colony. Il2rgfl/flE8IIICre and Il7ra
fl/flIl2rgfl/flE8IIICre mice were
kindly provided by A. Singer (NCI). The gc- and sgc-transgenic constructs
were generated by ligating a murine gc or sgc cDNA into human CD2
(hCD2) enhancer-promoter-based vectors, respectively, and injected intoFigure 7. sgc Overexpression Impairs T Cell Development and Homeo
(A) Surface gc chain staining on WT and sgcTg CD4+ T cells. Data are the summ
(B) sgc binding affinities to IL-7Ra determined by surface plasmon resonance. Bin
immobilized IL-7Ra proteins.
(C) Cell surface gc staining of Il2rgfl/flE8IIICre thymocytes incubated with recomb
Veh (BSA in PBS) and assessed with gc antibodies for surface gc staining. Histo
(D) Cell surface gc staining of Il2rgfl/flE8IIICre and Il7ra
fl/flIl2rgfl/flE8IIICre thymocyte
intensity (MFI) in TCRbhi thymocytes. Data are summary of two independent exp
(E) Total thymocyte numbers in WT and sgcTg mice. Results are the summary o
(F) T cell apoptosis in WT and sgcTg LN T cells. Caspase-3 activity was determ
Histograms show caspase-3 activity in indicated cells (left). Bar graphs show su
(G) Naive andmemory phenotype analysis ofWT and sgcTg LN T cells. Contour plo
CD8+ LN T cells, respectively (left). Bar graph shows naive CD4+ and CD8+ LN T
independent experiments.
Error bars represent mean and SEM.fertilized B6 oocytes to generate gcTg and sgcTg mice. Animal experiments
were approved by the National Cancer Institute Animal Care and Use Commit-
tee (ACUC), and all mice were cared for in accordance with US NIH guidelines.
Surface Plasmon Resonance
Purified mouse IL-2Rb ectodomain expressed from yeast was purchased
from MyBiosource and used without further modification. IL-2Rb was amine-
coupled to a CM5 sensor chip after buffer exchange into PBS (pH 7.4) via a
NAP-5 (GE Healthcare) column by similar methods described previously
(McElroy et al., 2012). Concentration series of monomer and dimer forms of in-
sect-cell-derived rsgc were injected over immobilized IL-2Rb at a flow rate of
25 ml/min via HBS-EP (pH 7.4). Surface plasmon resonance (SPR) experiments
were performed at 25C with a Biacore 3000 instrument (GE Healthcare). SPR
sensorgrams were double-referenced and trimmedwith BIAevaluation 4.1 (GE
Healthcare). Dose-response curves (Rmax versus [rsgcmonomer or dimer])
were fit with Prism5.0 (GraphPad). Experiments were performed in triplicate.
Detection of Soluble Cytokine and Receptor Levels
Serum sgc was detected in a sandwich ELISA with gc-specific polyclonal an-
tibodies (R&D Systems) as capture antibodies and biotin-conjugated gc-spe-
cific monoclonal antibodies (4G3; BD) as detection antibodies. Recombinant
sgc protein was used as positive control. IL-2, IFN-g, TNF-a, and IL-17A
were analyzed by ELISA according to the manufacturer’s instructions (R&D
Systems).
In Vitro CD4+ T Helper Cell Differentiation
NaiveCD4+Tcellswereelectronically sortedbygatingonCD62L+CD44loCD25
cells. Sorted cells were stimulated with plate-bound a-CD3 and a-CD28 and
cultured under nonskewing Th0 cell conditions (medium alone) or were differen-
tiated into Th17 cells with human TGF-b1 (5 ng/ml; Peprotech), mouse IL-6
(30 ng/ml; BD), anti-mouse IL-4 (10 mg/ml), and anti-mouse IFN-g (10 mg/ml).
Where indicated, human IL-2 (100 U/ml; NCI) or anti-mouse IL-2 (10 mg/ml;
Becton Dickinson) or mouse rsgc (4 mg/ml) was added to the cell culture.
Cell Proliferation Assay
Naive CD8 responder T cells were labeled with CFSE (carboxyfluorescein
diacetate succinimidyl ester; Invitrogen) and incubated with human IL-2
(10 mg/ml; Peprotech) for 2 or 3 days.
CD4+CD45RBhi T Cell Transfer-Induced Colitis
CD4+ T cells were purified fromWT, sgcTg, andmgcTgmice with the EasySep
mouse CD4+ T cell isolation kit (StemCell Technologies). CD4+CD45RBhi cells
were then electronically sorted by FACS. Rag2/mice were injected with 53
105 CD4+CD45RBhi T cells and monitored for 7 weeks for body weight change
and clinical signs of colitis. Experimental mice showing clinical signs of severe
colitis and a body weight loss of >20% were sacrificed according to the NCI
ACUC guidelines.
Statistical Analysis
Statistical differences were analyzed with Student’s two-tailed t test. Clinical
score comparisons between two groups were performed with nonparametricstasis
ary of four independent experiments.
ding sensorgrams and Kd of monomeric (left) and dimeric (right) sgc proteins to
inant sgc. Il2rgfl/flE8IIICre thymocytes were incubated for 2 hr with 4 mg rsgc or
grams show surface gc staining on DP and TCRbhi thymocytes.
s incubated with rsgc. Surface gc staining was assessed as mean fluorescence
eriments.
f eight independent experiments.
ined in naive CD44lo CD4+ or CD8+ LN T cells via CaspGLOW apoptosis kits.
mmary of three independent experiments (right).
ts showCD62L/CD44 andCD122/CD44 profiles and percentages of CD4+ and
cells numbers from WT and sgcTg mice (right). Data are the summary of ten
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Immunity
Soluble gc Receptor Controls Cytokine SignalingMann-Whitney test. Curves of body weight change were fitted with nonlinear
regression and group difference was examined by slope and intercept.
p values of less than 0.05 were considered significant. *p < 0.05, **p < 0.01,
***p < 0.001, and NS (not significant) (Student’s two-tailed t test).
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